Received Jun 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 72NF3 | ID |
ended done it intradermal and not intramuscular; administration was in the forearm; Cellulitis; This non-serious case was reported by a nurse via call center representative and described the occurrence of cellulitis in a 30-year-old male patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number 72NF3 with expiry date 23-JUN-2028) for prophylaxis. On 19-MAY-2026, the patient received Boostrix (intradermal). In MAY-2026, an unknown time after receiving Boostrix, the patient experienced cellulitis (Verbatim: Cellulitis). On 19-MAY-2026, the patient experienced intramuscular formulation administered by other route (Verbatim: ended done it intradermal and not intramuscular) and vaccine administered at inappropriate site (Verbatim: administration was in the forearm).The outcome of the cellulitis was unknown and the outcome of the intramuscular formulation administered by other route and vaccine administered at inappropriate site were not applicable. The reporter considered the cellulitis to be related to Boostrix. It was unknown if the reporter considered the cellulitis to be related to Boostrix Pre-Filled Syringe Device. The company considered the cellulitis to be related to Boostrix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:28-MAY-2026 The reporter administered a vaccine which was tdap, but in the wrong way so, she ended done it intradermal and not intramuscular. The reporter said that the administration was in the forearm, it caused cellulitis, antibiotic was administered and the reaction was diminishing.